REmotely Supervised Exercise Therapy Trial 2 (RESET2)

Mid and South Essex NHS Foundation Trust

Status: Enrolling

Conditions: Claudication, Intermittent; Peripheral Arterial Disease

Treatments: Behavioral: Remotely supervised exercise programme; Behavioral: Self-directed exercise

Study type: Interventional

Funder types: Other

Identifiers

NCT04925219

2987694

Details and patient eligibility

About

Supervised exercise for intermittent claudication is a first line therapy for peripheral arterial disease, as recommended by the National Institute for Health and Clinical Excellence and the European Society for Vascular Surgery. However 2/3 of British trusts cannot implement this due to gym availability, costs, travel time and the requirement for social distancing.

During the COVID-19 lockdown the investigators successfully performed a feasibility study for remotely supervised exercise using an electronic walking log and fortnightly video calls with a physiotherapist.

RESET2 aims to compare the benefits of and adherence to remotely supervised exercise with self-directed exercise to absolute walking distance.

Full description

Design A single centre, pilot, randomised controlled trial at Mid and South Essex Hospitals Foundation Trust. The study is unfunded and sponsored by Mid and South Essex Hospitals National Health Service Trust.

Sample size This is a pilot randomised controlled trial to generate a sample size calculation for a larger trial.

Based on the feasibility data from RESET1 and the published results of supervised exercise, the expected benefit of remotely supervised exercise is about 180 metres extra walking distance, with a standard deviation of 150m in both groups.

With alpha=0.05 (5% false positive rate) and beta=0.1 (90% power), 16 patients in each arm are required to demonstrate a mean difference in the primary endpoint of 180 metres, using a 2 sided t-test (MedCalc statistical software, Belgium).

The sample size will be 20+20 patients from Mid and South Essex Trust vascular outpatient clinics.

Follow up There will be 3 assessment visits: baseline, 3 months and 6 months performed with a study clinician.

The primary endpoint will be measured blind to treatment allocation by asking the patient to walk along a flat, hospital corridor until they need to stop due to leg pain. This will be measured at 0, 3 and 6 months.

The secondary endpoint will be through patient questionnaires and scored by an independent observer at baseline, 3 and 6 months.

Ankle-brachial pressure index will be measured by an independent vascular scientist at the start and end of the study.

Patient satisfaction will be measured at 3 months using a self-reported questionnaire.

Adherence to exercise will be measured through submission of walking logs at 1, 2 and 3 months.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Arterial claudication with ABPI <0.9 or post-treadmill pressure drop of >20mmHg
• Able to walk 50 metres unaided
• Willing to try and give up smoking
• Willing to take antiplatelet, rivaroxaban and statin
• Has a smartphone or pedometer or watch
• Has an email account
• Adult > 18 years old
• Able to give informed consent

Exclusion criteria

• Nocturnal foot pain or tissue loss
• Use of walking stick, frame or wheelchair
• Severe COPD or heart failure or arthritis
• Home oxygen
• Major amputation and non-limb wearer
• Severe hearing or visual impairment
• Prior failed exercise regime
• Prior falls
• Cognitive impairment
• Unable to work due to severity of claudication

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

Remotely supervised exercise

Experimental group

Description:

Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD. Intervention = electronic walking log and fortnightly video/telephone call with physiotherapist for 3 months.

Treatment:

Behavioral: Remotely supervised exercise programme

Self-directed exercise

Active Comparator group

Description:

Best medical therapy including aspirin 75mg od + rivaroxaban 2.5mg bd (if not tolerated clopidogrel 75mg od), atorvastatin 80mg and smoking cessation referral as per NICE guideline for PAD. Control = electronic walking log and instructions to exercise 4 times per week for 3 months

Treatment:

Behavioral: Self-directed exercise